查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1980184

生物标誌物市场规模、份额、成长及全球产业分析：按类型和应用划分，区域洞察及2026-2034年预测

Biomarkers Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 110 Pages | 商品交期: 请询问到货日

价格

生物标誌物市场成长要素

全球生物标记市场预计在2025年达到869.5亿美元，2026年成长至975亿美元，并在2034年达到2,175.8亿美元，预测期内复合年增长率（CAGR）高达12.2%。北美将在2025年引领市场，占36.93%的市占率。这主要得益于个人化医疗的积极应用、主要企业的巨额投资以及先进的医疗基础设施。

生物标记是能够反映器官、组织或细胞生物学状态的可测量指标。它们在疾病诊断、药物研发、安全性评估和生物医学研究中至关重要。生物标记可根据其功能（例如诊断、预后、预测或其他生物标记功能）及其生物学特征（例如基因组学、蛋白质组学和代谢体学）进行广泛分类。

市场驱动因素

全球生物标记市场的主要驱动力是生物标记诊断应用的不断扩展。生物标记在个人化医疗中发挥着至关重要的作用，有助于根据患者的临床和基因特征优化治疗方案。这在肿瘤学领域尤其重要，因为基于生物标记的治疗方法能够提高治疗效果。癌症、心血管疾病和神经退化性疾病的日益普遍也进一步推动了市场需求。

疾病诊断技术的进步、对基于生物标记的药物研发投入的增加以及伴随诊断的普及是推动市场成长的关键因素。例如，辉瑞公司的Selgently（Maraviloc）利用一种名为Trofile的生物标记检测来评估HIV患者对治疗的反应。同样，DiamiR公司在2019年因其对脑源性微型RNA作为神经退化外周生物标誌物的研究而获得了阿兹海默症基金会的奖项。

市场限制因素

挑战包括研发成本高、监管障碍以及生物标记检测需要专用设备。一些新兴市场认知度较低，以及将生物标记数据整合到临床决策中的复杂性，也可能是阻碍成长的因素。

細項分析

适应症：

  • 预计到 2025 年，肿瘤学将成为市场的主要驱动力，并在 2026 年保持其最大市场份额 49.44% 的地位，这主要得益于癌症患病率的上升以及基于生物标誌物的诊断方法在标靶治疗中的日益普及。
  • 由于肌钙蛋白等生物标记在心血管疾病诊断的应用日益广泛，循环系统领域正在蓬勃发展。
  • 神经病学和其他适应症是新兴领域，其发展动力来自神经退化性疾病疾病和罕见疾病的生物标记研究。

按最终用户划分：

  • 诊断和研究实验室是最大的终端用户群体，并得到了生物标记开发的大量津贴和投资的支持，预计到 2026 年将占市场份额的 52.89%。
  • 製药和生物技术公司、医院和专科诊所也是推动其应用的其他终端用户。

区域趋势

北美：

  • 市场规模：预计到 2025 年将达到 321.2 亿美元，到 2026 年将达到 358.7 亿美元。
  • 推动这一成长的主要因素包括个人化医疗的广泛应用、研发领域的大规模投资以及有利的监管核准。预计到2026年，光是美国市场规模就将达到311.7亿美元。

欧洲：

  • 欧盟体外诊断医疗设备法规结构（IVDR）、完善的临床研究基础设施以及生物技术公司与医疗机构之间的合作，为该市场提供了支持。预计2026年，英国市场规模将达46.2亿美元，德国市场规模将达80.2亿美元。

亚太地区：

  • 由于癌症和心血管疾病的日益普遍，预计市场将显着增长。到2026年，日本市场预计将达到73.4亿美元，中国66.6亿美元，印度26.5亿美元。对基于生物标记的药物研发投入的增加正在推动该技术的应用。

中东、非洲和拉丁美洲：

  • 由于全球公司的进入、医疗基础设施的改善以及对基于生物标誌物的诊断的日益重视，新兴地区有望实现成长。

主要市场参与者

生物标记市场高度分散，由罗氏、雅培和赛默飞世尔科技等公司主导，并受益于强大的研发实力和诊断检测领域的创新。其他主要企业包括Bio-Rad Laboratories、CENTOGENE NV、Axon Medchem、Sino Biological、R&D Systems、BioVision和Myriad RBM。

目录

第一章：引言

第二章执行摘要

第三章 市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机会

第四章：主要考虑因素

  • 主要市场参与者推出新产品
  • 按疾病分類的主要国家/地区，2025 年患病率
  • 2025年主要国家及地区癌症发生率
  • 产业重大发展动态－併购与合作
  • 个人化医疗中的生物标记概述

第五章：2021-2034年全球生物标记市场分析、洞察与预测

  • 主要发现与总结
  • 市场分析、洞察与预测：按指标
    • 肿瘤学
    • 循环系统
    • 神经病学
    • 其他的
  • 市场分析、洞察与预测：按最终用户划分
    • 製药和生物技术公司
    • 诊断与研究实验室
    • 医院和专科诊所
    • 其他的
  • 市场分析、洞察与预测：按地区划分
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章：北美生物标记市场分析、洞察与预测（2021-2034年）

  • 国家
    • 我们
    • 加拿大

第七章：欧洲生物标记市场分析、洞察与预测（2021-2034年）

  • 国家
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪地那维亚
    • 其他欧洲国家

第八章：亚太生物标记市场分析、洞察与预测（2021-2034年）

  • 国家
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 东南亚
    • 其他亚太国家

第九章：拉丁美洲生物标记市场分析、洞察与预测（2021-2034年）

  • 国家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲国家

第十章：中东和非洲生物标记市场分析、洞察与预测（2021-2034年）

  • 国家
    • 海湾合作委员会国家
    • 南非
    • 其他中东和非洲国家

第十一章 竞争分析

  • 主要行业趋势
  • 全球市占率分析（2025 年）
  • 公司简介
    • F. Hoffmann-La Roche Ltd.
    • Abbott
    • Thermo Fisher Scientific
    • Bio-Rad Laboratories, Inc
    • CENTOGENE NV
    • Axon Medchem
    • Sino Biological Inc.
    • R&D System
    • BioVision Inc.
    • Myriad RBM
    • Other Prominent Players

第十二章 战略建议

Product Code: FBI102173

Growth Factors of biomarkers Market

The global biomarkers market was valued at USD 86.95 billion in 2025 and is projected to grow to USD 97.5 billion in 2026, reaching USD 217.58 billion by 2034, reflecting a robust CAGR of 12.2% during the forecast period. North America dominated the market in 2025, accounting for a 36.93% share, driven by strong adoption in personalized medicine, significant investments by key players, and advanced healthcare infrastructure.

Biomarkers, or biological markers, are measurable indicators of the biological state of an organ, tissue, or cell. They are critical in disease diagnosis, drug discovery, safety assessment, and biomedical research. Biomarkers are broadly classified based on function, including diagnostic, prognostic, predictive, and other biomarkers, and on biological properties such as genomics, proteomics, and metabolomics.

Market Drivers

The global biomarkers market is primarily driven by the growing diagnostic applications of biomarkers. Biomarkers play an essential role in personalized medicine, helping tailor treatment plans based on a patient's clinical and genetic profile. This is particularly valuable in oncology, where biomarker-guided therapies enhance treatment efficacy. The increasing prevalence of cancer, cardiovascular, and neurodegenerative diseases further fuels demand.

Technological advancements in disease diagnosis, rising investment in biomarker-based drug discovery, and adoption of companion diagnostics are key factors accelerating market growth. For example, Pfizer's Selzentry (Maraviroc) utilizes the Trofile assay biomarker to determine patient response to HIV treatment. Similarly, DiamiR received an award from the Alzheimer's Drug Discovery Foundation in 2019 for research on circulating brain-enriched microRNAs as peripheral biomarkers of neurodegeneration.

Market Restraints

Challenges include high research and development costs, regulatory hurdles, and the need for specialized equipment for biomarker detection. Limited awareness in some emerging markets and the complexity of integrating biomarker data into clinical decision-making may also restrain growth.

Segmentation Analysis

By Indication:

  • Oncology dominated the market in 2025 and is expected to hold the largest share in 2026 with 49.44%, driven by rising cancer prevalence and increased use of biomarker-based diagnostics for targeted therapies.
  • Cardiology is growing due to the increasing use of biomarkers like troponin for diagnosing cardiovascular diseases.
  • Neurology and other indications are emerging segments, fueled by biomarker research in neurodegenerative and rare diseases.

By End User:

  • Diagnostics and research laboratories are the largest end-user segment, expected to hold 52.89% of the market in 2026, supported by extensive grants and investment in biomarker development.
  • Pharmaceutical & biotechnology companies, hospitals, and specialty clinics represent other end-users driving adoption.

Regional Insights

North America:

  • Market size: USD 32.12 billion in 2025, projected USD 35.87 billion in 2026.
  • Growth is fueled by strong adoption in personalized medicine, extensive R&D investment, and favorable regulatory approvals. The U.S. market alone is projected to reach USD 31.17 billion in 2026.

Europe:

  • Supported by the EU's regulatory framework for in-vitro diagnostics (IVDR), robust clinical research infrastructure, and collaborations between biotech companies and healthcare institutions. The UK market is projected at USD 4.62 billion and Germany at USD 8.02 billion by 2026.

Asia Pacific:

  • Market growth is expected to be significant due to the increasing prevalence of cancer and cardiovascular diseases. The Japan market is projected at USD 7.34 billion, China at USD 6.66 billion, and India at USD 2.65 billion by 2026. Rising investments in biomarker-based drug discovery are boosting adoption.

Middle East, Africa, and Latin America:

  • Emerging regions are witnessing growth due to the entry of global players, improved healthcare infrastructure, and increased focus on biomarker-based diagnostics.

Key Market Players

The biomarkers market is highly fragmented, led by F. Hoffmann-La Roche Ltd., Abbott, and Thermo Fisher Scientific, Inc., supported by strong R&D and innovation in diagnostic assays. Other notable players include Bio-Rad Laboratories, CENTOGENE N.V., Axon Medchem, Sino Biological Inc., R&D Systems, BioVision Inc., and Myriad RBM.

Recent Developments:

  • January 2025: Launch of AI-engineered designer proteins for regenerative medicine.
  • February 2025: Expansion of RNAscope(TM) probe portfolio for biomarker validation.
  • November 2024: Achieved IVDR certification for R&D Systems hematology controls.
  • May 2023: FDA clearance for B*R*A*H*M*S PlGF plus KRYPTOR immunoassays.

Conclusion

The biomarkers market is set for significant growth, from USD 86.95 billion in 2025 to USD 217.58 billion by 2034, fueled by the increasing adoption of personalized medicine, advancements in diagnostics, and the rising prevalence of chronic diseases. Strong investments in R&D, the introduction of novel biomarkers, and collaborations between biotech companies are expected to further drive market expansion across regions, particularly in North America and Asia Pacific.

Segmentation By Indication

  • Oncology
  • Cardiology
  • Neurology
  • Others

By End User

  • Pharmaceutical & Biotechnology Companies
  • Diagnostics & Research Laboratories
  • Hospitals & Specialty Clinics
  • Others

By Geography

  • North America (U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
  • Latin America (Brazil, Mexico, and Rest of Latin America)
  • Middle East & Africa (South Africa, GCC and Rest of the Middle East & Africa)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities

4. Key Insights

  • 4.1. New Product Launches, by Key Market Players
  • 4.2. Prevalence by Disease Indication, By Key Countries/ Region, 2025
  • 4.3. Incidence of Cancer, By Key Countries/ Key Region,2025
  • 4.4. Key industry Developments - Mergers, Acquisitions and Partnerships
  • 4.5. Overview of Biomarkers In Personalized Medicine

5. Global Biomarkers Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Key Findings / Summary
  • 5.2. Market Analysis, Insights and Forecast - By Indication
    • 5.2.1. Oncology
    • 5.2.2. Cardiology
    • 5.2.3. Neurology
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By End User
    • 5.3.1. Pharmaceutical & Biotechnology Companies
    • 5.3.2. Diagnostics & Research Laboratories
    • 5.3.3. Hospitals & Specialty Clinics
    • 5.3.4. Others
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Biomarkers Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Key Findings / Summary
  • 6.2. Market Analysis, Insights and Forecast - By Indication
    • 6.2.1. Oncology
    • 6.2.2. Cardiology
    • 6.2.3. Neurology
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By End User
    • 6.3.1. Pharmaceutical & Biotechnology Companies
    • 6.3.2. Diagnostics & Research Laboratories
    • 6.3.3. Hospitals & Specialty Clinics
    • 6.3.4. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Biomarkers Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Key Findings / Summary
  • 7.2. Market Analysis, Insights and Forecast - By Indication
    • 7.2.1. Oncology
    • 7.2.2. Cardiology
    • 7.2.3. Neurology
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By End User
    • 7.3.1. Pharmaceutical & Biotechnology Companies
    • 7.3.2. Diagnostics & Research Laboratories
    • 7.3.3. Hospitals & Specialty Clinics
    • 7.3.4. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Biomarkers Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Key Findings / Summary
  • 8.2. Market Analysis, Insights and Forecast - By Indication
    • 8.2.1. Oncology
    • 8.2.2. Cardiology
    • 8.2.3. Neurology
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By End User
    • 8.3.1. Pharmaceutical & Biotechnology Companies
    • 8.3.2. Diagnostics & Research Laboratories
    • 8.3.3. Hospitals & Specialty Clinics
    • 8.3.4. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Biomarkers Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Key Findings / Summary
  • 9.2. Market Analysis, Insights and Forecast - By Indication
    • 9.2.1. Oncology
    • 9.2.2. Cardiology
    • 9.2.3. Neurology
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By End User
    • 9.3.1. Pharmaceutical & Biotechnology Companies
    • 9.3.2. Diagnostics & Research Laboratories
    • 9.3.3. Hospitals & Specialty Clinics
    • 9.3.4. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Biomarkers Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Key Findings / Summary
  • 10.2. Market Analysis, Insights and Forecast - By Indication
    • 10.2.1. Oncology
    • 10.2.2. Cardiology
    • 10.2.3. Neurology
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By End User
    • 10.3.1. Pharmaceutical & Biotechnology Companies
    • 10.3.2. Diagnostics & Research Laboratories
    • 10.3.3. Hospitals and Specialty Clinics
    • 10.3.4. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 10.4.1. GCC Countries
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Key Industry Developments
  • 11.2. Global Market Share Analysis (2025)
  • 11.3. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
    • 11.3.1. F. Hoffmann-La Roche Ltd.
      • 11.3.1.1. Overview,
      • 11.3.1.2. Products & services,
      • 11.3.1.3. SWOT analysis,
      • 11.3.1.4. Recent developments,
      • 11.3.1.5. strategies,
      • 11.3.1.6. financials (based on availability)
    • 11.3.2. Abbott
      • 11.3.2.1. Overview,
      • 11.3.2.2. Products & services,
      • 11.3.2.3. SWOT analysis,
      • 11.3.2.4. Recent developments,
      • 11.3.2.5. strategies,
      • 11.3.2.6. financials (based on availability)
    • 11.3.3. Thermo Fisher Scientific
      • 11.3.3.1. Overview,
      • 11.3.3.2. Products & services,
      • 11.3.3.3. SWOT analysis,
      • 11.3.3.4. Recent developments,
      • 11.3.3.5. strategies,
      • 11.3.3.6. financials (based on availability)
    • 11.3.4. Bio-Rad Laboratories, Inc
      • 11.3.4.1. Overview,
      • 11.3.4.2. Products & services,
      • 11.3.4.3. SWOT analysis,
      • 11.3.4.4. Recent developments,
      • 11.3.4.5. strategies,
      • 11.3.4.6. financials (based on availability)
    • 11.3.5. CENTOGENE N.V.
      • 11.3.5.1. Overview,
      • 11.3.5.2. Products & services,
      • 11.3.5.3. SWOT analysis,
      • 11.3.5.4. Recent developments,
      • 11.3.5.5. strategies,
      • 11.3.5.6. financials (based on availability)
    • 11.3.6. Axon Medchem
      • 11.3.6.1. Overview,
      • 11.3.6.2. Products & services,
      • 11.3.6.3. SWOT analysis,
      • 11.3.6.4. Recent developments,
      • 11.3.6.5. strategies,
      • 11.3.6.6. financials (based on availability)
    • 11.3.7. Sino Biological Inc.
      • 11.3.7.1. Overview,
      • 11.3.7.2. Products & services,
      • 11.3.7.3. SWOT analysis,
      • 11.3.7.4. Recent developments,
      • 11.3.7.5. strategies,
      • 11.3.7.6. financials (based on availability)
    • 11.3.8. R&D System
      • 11.3.8.1. Overview,
      • 11.3.8.2. Products & services,
      • 11.3.8.3. SWOT analysis,
      • 11.3.8.4. Recent developments,
      • 11.3.8.5. strategies,
      • 11.3.8.6. financials (based on availability)
    • 11.3.9. BioVision Inc.
      • 11.3.9.1. Overview,
      • 11.3.9.2. Products & services,
      • 11.3.9.3. SWOT analysis,
      • 11.3.9.4. Recent developments,
      • 11.3.9.5. strategies,
      • 11.3.9.6. financials (based on availability)
    • 11.3.10. Myriad RBM
      • 11.3.10.1. Overview,
      • 11.3.10.2. Products & services,
      • 11.3.10.3. SWOT analysis,
      • 11.3.10.4. Recent developments,
      • 11.3.10.5. strategies,
      • 11.3.10.6. financials (based on availability)
    • 11.3.11. Other Prominent Players
      • 11.3.11.1. Overview,
      • 11.3.11.2. Products & services,
      • 11.3.11.3. SWOT analysis,
      • 11.3.11.4. Recent developments,
      • 11.3.11.5. strategies,
      • 11.3.11.6. financials (based on availability)

12. Strategic Recommendation

List of Tables

  • Table 1: Global Biomarkers Market Revenue (US$ Mn) Forecast, by Indication, 2021-2034
  • Table 2: Global Biomarkers Market Revenue (US$ Mn) Forecast, by End User, 2021-2034
  • Table 3: Global Biomarkers Market Revenue (US$ Mn) Forecast, by Region, 2021-2034
  • Table 4: North America Biomarkers Market Revenue (US$ Mn) Forecast, by Indication, 2021-2034
  • Table 5: North America Biomarkers Market Revenue (US$ Mn) Forecast, by End User, 2021-2034
  • Table 6: North America Biomarkers Market Revenue (US$ Mn) Forecast, By Country, 2021-2034
  • Table 7: Europe Biomarkers Market Revenue (US$ Mn) Forecast, by Indication, 2021-2034
  • Table 8: Europe Biomarkers Market Revenue (US$ Mn) Forecast, by End User, 2021-2034
  • Table 9: Europe Biomarkers Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 10: Asia Pacific Biomarkers Market Revenue (US$ Mn) Forecast, by Indication, 2021-2034
  • Table 11: Asia Pacific Biomarkers Market Revenue (US$ Mn) Forecast, by End User, 2021-2034
  • Table 12: Asia Pacific Biomarkers Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Latin America Biomarkers Market Revenue (US$ Mn) Forecast, by Indication, 2021-2034
  • Table 14: Latin America Biomarkers Market Revenue (US$ Mn) Forecast, by End User, 2021-2034
  • Table 15: Latin America Biomarkers Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Middle East & Africa Biomarkers Market Revenue (US$ Mn) Forecast, by Indication, 2021-2034
  • Table 17: Middle East & Africa Biomarkers Market Revenue (US$ Mn) Forecast, by End User, 2021-2034
  • Table 18: Middle East & Africa Biomarkers Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Biomarkers Market Revenue Breakdown (US$ Mn, %) by Region, 2025 & 2034
  • Figure 2: Global Biomarkers Market Value Share (%), by Indication 2025 & 2034
  • Figure 3: Global Biomarkers Market Forecast (US$ Mn), by Oncology, 2021-2034
  • Figure 4: Global Biomarkers Market Forecast (US$ Mn), by Cardiology, 2021-2034
  • Figure 5: Global Biomarkers Market Forecast (US$ Mn), by Neurology, 2021-2034
  • Figure 6: Global Biomarkers Market Forecast (US$ Mn), by Others, 2021-2034
  • Figure 7: Global Biomarkers Market Value Share (%), by End User, 2025 & 2034
  • Figure 8: Global Biomarkers Market Forecast (US$ Mn), by Pharmaceutical and Biotechnology Companies, 2021-2034
  • Figure 9: Global Biomarkers Market Forecast (US$ Mn), by Diagnostics and Research Laboratories, 2021-2034
  • Figure 10: Global Biomarkers Market Forecast (US$ Mn), by Hospitals and Specialty Clinics, 2021-2034
  • Figure 11: Global Biomarkers Market Forecast (US$ Mn), by Others, 2021-2034
  • Figure 12: Global Biomarkers Market Value (US$ Mn), by Region, 2025 & 2034
  • Figure 13: North America Biomarkers Market Value (US$ Mn), by Indication, 2025 & 2034
  • Figure 14: North America Biomarkers Market Value Share (%), by Indication, 2025
  • Figure 15: North America Biomarkers Market Value (US$ Mn), by End User, 2025 & 2034
  • Figure 16: North America Biomarkers Market Value Share (%), by End User, 2025
  • Figure 17: North America Biomarkers Market Value (US$ Mn), By Country, 2025 & 2034
  • Figure 18: North America Biomarkers Market Value Share (%), By Country, 2025
  • Figure 19: Europe Biomarkers Market Value (US$ Mn), by Indication, 2025 & 2034
  • Figure 20: Europe Biomarkers Market Value Share (%), by Indication, 2025
  • Figure 21: Europe Biomarkers Market Value (US$ Mn), by End User, 2025 & 2034
  • Figure 22: Europe Biomarkers Market Value Share (%), by End User, 2025
  • Figure 23: Europe Biomarkers Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 24: Europe Biomarkers Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 25: Asia Pacific Biomarkers Market Value (US$ Mn), by Indication, 2025 & 2034
  • Figure 26: Asia Pacific Biomarkers Market Value Share (%), by Indication, 2025
  • Figure 27: Asia Pacific Biomarkers Market Value (US$ Mn), by End User, 2025 & 2034
  • Figure 28: Asia Pacific Biomarkers Market Value Share (%), by End User, 2025
  • Figure 29: Asia Pacific Biomarkers Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 30: Asia Pacific Biomarkers Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 31: Latin America Biomarkers Market Value (US$ Mn), by Indication, 2025 & 2034
  • Figure 32: Latin America Biomarkers Market Value Share (%), by Indication, 2025
  • Figure 33: Latin America Biomarkers Market Value (US$ Mn), by End User, 2025 & 2034
  • Figure 34: Latin America Biomarkers Market Value Share (%), by End User, 2025
  • Figure 35: Latin America Biomarkers Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Latin America Biomarkers Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Middle East & Africa Biomarkers Market Value (US$ Mn), by Indication, 2025 & 2034
  • Figure 38: Middle East & Africa Biomarkers Market Value Share (%), by Indication, 2025
  • Figure 39: Middle East & Africa Biomarkers Market Value (US$ Mn), by End User, 2025 & 2034
  • Figure 40: Middle East & Africa Biomarkers Market Value Share (%), by End User, 2025
  • Figure 41: Middle East & Africa Biomarkers Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 42: Middle East & Africa Biomarkers Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 43: Global Biomarkers Market Share (%), By Company, 2025